Teva Pharmaceutical Deal History & Licensing Activity
Teva Pharmaceutical is a large pharma headquartered in Israel. Over the past three years, Teva Pharmaceutical has been involved in 6 licensing and acquisition transactions, with a primary focus on Small Molecules (4 deals). The company currently has 23 active clinical trials, primarily in Autoimmune.
Deals (12mo)
4
Active Trials
23
Top Modality
Small Molecules
Focus Area
Autoimmune
Teva Pharmaceutical Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Teva Pharmaceutical in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| IGALMI (dexmedetomidine sublingual film) | Teva | Small Molecules | Approved | acquisition | Aug 28, 2026 |
| biosimilar ocrelizumab | Teva Pharmaceutical Industries | Antibodies | Unknown | license | Jul 9, 2026 |
| ecopipam | Teva Pharmaceutical Industries Ltd. | Small Molecules | Phase 3 | acquisition | Jun 10, 2026 |
| TEV-'408 | Royalty Pharma | Small Molecules | Phase 2 | co development | Jan 11, 2026 |
Teva Pharmaceutical Pipeline Focus
Therapeutic areas and modalities where Teva Pharmaceutical is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Teva Pharmaceutical Strategic Signals
Key indicators of Teva Pharmaceutical's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
Teva Pharmaceutical Clinical Pipeline
Teva Pharmaceutical has 23 active clinical trials across 6 development phases.
2
Phase 4
1
Not Applicable
4
Unknown
3
Phase 1
6
Phase 2
7
Phase 3
See How Your Asset Matches Teva Pharmaceutical's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Autoimmune assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Neurology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for neurology
Immunology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for immunology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Teva Pharmaceutical Licensing & Deal Activity
Teva Pharmaceutical is a large pharma company based in Israel that has been actively engaged in licensing transactions across the biopharma landscape. With 6 deals over the past three years, Teva Pharmaceutical ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Teva Pharmaceutical include Autoimmune (11 deals and trials), Neurology (5 deals and trials), Immunology (5 deals and trials), and CNS Disorders (3 deals and trials). In terms of modality, Teva Pharmaceutical has shown particular interest in small molecules, small molecules, antibodies.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Teva Pharmaceutical and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Teva Pharmaceutical's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.